Business
BioAge is a clinical-stage biopharmaceutical company developing product candidates for metabolic diseases by targeting aging biology.
BioAge added Novartis collaboration revenue but losses and cash burn widened as BGE-102 became the lead program.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage metabolic disease biotechNote
- Revenue — $9.0M collaboration revenueOK
- Loss — Net loss widened 13.4%Watch
- FCF — FCF deficit widened 58.7%Watch
- Debt — Long-term debt reduced to zeroOK
- Insiders — 0 purchases / 8 salesWatch
- Accounting — Altman-Z 3.75 safeNote
Where the revenue comes from
Fiscal 2025, as BioAge Labs, Inc. reports it. History and quarterly detail are in the app.
- Deferred Revenue$6.7M
- Reimbursable Costs$2.2M
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BioAge Labs, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.